ACRS — Aclaris Therapeutics Share News
0.000.00%
Last trade - 00:00- $532.87m
- $441.32m
- $7.83m
Brief: Aclaris Therapeutics Terminates Employment Of Chief Medical Officer Gail Cawkwell on Jan 31
U.S. STOCKS ON THE MOVE-Halozyme, Scorpio Tankers
U.S. STOCKS ON THE MOVE-Halozyme, Scorpio Tankers, Advanced Micro Devices
U.S. STOCKS ON THE MOVE-InMode, Carrols Restaurant, Tesla
Aclaris Therapeutics jumps on starting strategic business review
Brief: Aclaris Therapeutics AppointS Neal Walker As Interim CEO
U.S. STOCKS ON THE MOVE-T Rowe Price, Sunoco, gold miners
U.S. STOCKS ON THE MOVE-Netflix, Wabtec, Chesapeake Energy
U.S. STOCKS ON THE MOVE-American Airlines, Oil companies, Salesforce
Aclaris down as BTIG downgrades to 'neutral' on dermatitis drug trial setback
U.S. STOCKS ON THE MOVE-Virgin Galactic, Meta Platforms, EchoStar
U.S. STOCKS ON THE MOVE-Palo Alto Networks, Masimo, Tigo Energy
Aclaris falls after mid-stage trial setback for dermatitis drug
U.S. STOCKS ON THE MOVE-Intuitive Surgical, Home Depot, SMART Global
Brief: Aclaris Therapeutics Announces Top-Line Results From 4-Week Phase 2B Trial Of ATI-1777 For Mild To Severe Atopic Dermatitis
Aclaris falls after mid-stage trial setback for dermatitis drug
U.S. STOCKS ON THE MOVE-Coinbase Global, Spirit AeroSystems, Crown Castle
Aclaris Therapeutics falls after delay on skin disease drug data
Brief: Aclaris Therapeutics Announced A Reduction Of Its Workforce By Approximately 46%